Clinical trial · Observational
Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With Explainability
Prediction of Microvascular Invasion in HCC Using Spatiotemporal Radiomics of Contrast-enhanced Ultrasound: a Deep Learning Model With Transcriptomics Correlation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An artificial intelligence (AI) model to predict MVI of HCC using contrast-enhanced ultrasound was constructed. This model also has biological explainability. The investigators named it as MAPUSE (MVI AI prediction via contrast-enhanced ultrasound with explainability). The goal of MAPUSE study is to prospectively test the performance of MAPUSE model on MVI prediction and its biological correlation in different geographical areas of China.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC - Hepatocellular Carcinoma | Hepatocellular Carcinoma | PROBABILISTIC | 0.70 |
| Microvascular Invasion (MVI) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| the MAPUSE model | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Chinese PLA General Hospital Cohort
- description
- Patients from Chinese PLA General Hospital (northern China) after surgical treatment
- interventionNames
- Diagnostic Test: the MAPUSE model
- label
- the First Affiliated Hospital of Sun Yat-sen University Cohort
- description
- Patients from the First Affiliated Hospital of Sun Yat-sen University (southern China) after surgical treatment
- interventionNames
- Diagnostic Test: the MAPUSE model
Primary outcomes (1)
- measure
- area under operating characteristic curves (AUC)
- timeFrame
- From preoperative enrollment to the postoperative confirmation of pathological diagnosis (7-15 days postopertively)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age \>18 years old. 2. The HCC diagnosis and the presence of MVI were confirmed by surgical pathology. 3. Complete and clear CEUS videos obtained within two weeks preoperatively. Exclusion Criteria: 1. Unqualified CEUS images. 2. Missing surgical pathological diagnosis. 3. Lesions underwent local treatments. 4. Non-HCC diagnosis
References
Publications (0)
Data not yet available